Minimal residual disease in multiple myeloma.
作者信息
Munshi Nikhil C, Anderson Kenneth C
出版信息
J Clin Oncol. 2013 Jul 10;31(20):2523-6. doi: 10.1200/JCO.2013.49.2124. Epub 2013 Jun 3.
Abstract
摘要
相似文献
1
Minimal residual disease in multiple myeloma.多发性骨髓瘤中的微小残留病
J Clin Oncol. 2013 Jul 10;31(20):2523-6. doi: 10.1200/JCO.2013.49.2124. Epub 2013 Jun 3.
2
Minimal residual disease: what are the minimum requirements?微小残留病：最低要求是什么？
J Clin Oncol. 2014 Feb 10;32(5):475-6. doi: 10.1200/JCO.2013.52.1955. Epub 2014 Jan 13.
3
Reply to M. Roschewski et al.对M. 罗谢夫斯基等人的回复
J Clin Oncol. 2014 Feb 10;32(5):478. doi: 10.1200/JCO.2013.53.0998. Epub 2014 Jan 13.
4
Reply to M. Roschewski et al.对M. 罗谢夫斯基等人的回复
J Clin Oncol. 2014 Feb 10;32(5):476-7. doi: 10.1200/JCO.2013.53.0980. Epub 2014 Jan 13.
5
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.多参数流式细胞术检测多发性骨髓瘤微小残留病：对 MRC 骨髓瘤 IX 研究结果的影响。
J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3.
6
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.多参数流式细胞术微小残留病评估在复发多发性骨髓瘤中的预后价值
Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7.
7
Consolidation therapy in myeloma: a consolidated approach?骨髓瘤的巩固治疗：一种巩固的方法？
Blood. 2012 Jul 5;120(1):2-3. doi: 10.1182/blood-2012-04-425231.
8
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤非清髓性同种异体移植后微小残留病的前瞻性分子监测
Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.
9
Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.硼替佐米与美法仑预处理可提高接受单次自体干细胞移植的多发性骨髓瘤患者的完全缓解率及微小残留病阴性率。
Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8.
10
High-dose therapy in multiple myeloma.多发性骨髓瘤的大剂量疗法。
Ann Oncol. 2002;13 Suppl 4:49-54. doi: 10.1093/annonc/mdf638.
引用本文的文献
1
[Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)].《基于骨髓样本的多发性骨髓瘤微小残留病检测中国专家共识（2024年）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):534-541. doi: 10.3760/cma.j.cn121090-20240430-00167.
2
Steps towards a Multiple Myeloma Cure?迈向多发性骨髓瘤治愈的步骤？
J Pers Med. 2022 Sep 3;12(9):1451. doi: 10.3390/jpm12091451.
3
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
4
Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.韩国多发性骨髓瘤患者免疫球蛋白基因重排：使用下一代测序进行克隆性评估和库分析。
PLoS One. 2021 Jun 24;16(6):e0253541. doi: 10.1371/journal.pone.0253541. eCollection 2021.
5
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.多发性骨髓瘤中的微小残留病：临床实践中的最新技术与应用
J Pers Med. 2020 Sep 10;10(3):120. doi: 10.3390/jpm10030120.
6
comparison of the cytotoxic effects of statins on U266 myeloma cell line.比较他汀类药物对 U266 骨髓瘤细胞系的细胞毒性作用。
Indian J Med Res. 2019 Dec;150(6):630-634. doi: 10.4103/ijmr.IJMR_672_18.
7
[Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].[十色流式细胞术监测多发性骨髓瘤微小残留病的临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2019 Sep 14;40(9):720-725. doi: 10.3760/cma.j.issn.0253-2727.2019.09.002.
8
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates.根据I期总缓解率预测多发性骨髓瘤的成功阶段进展和监管批准。
JCO Clin Cancer Inform. 2017 Nov;1:1-14. doi: 10.1200/CCI.17.00055.
9
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.铜 64 标记的达妥木单抗作为多发性骨髓瘤的 PET/CT 成像示踪剂。
Blood. 2018 Feb 15;131(7):741-745. doi: 10.1182/blood-2017-09-807263. Epub 2018 Jan 4.
10
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
本文引用的文献
1
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.多参数流式细胞术检测多发性骨髓瘤微小残留病：对 MRC 骨髓瘤 IX 研究结果的影响。
J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3.
2
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.硼替佐米、沙利度胺和地塞米松联合或不联合环磷酰胺作为诱导治疗方案治疗初治多发性骨髓瘤的随机 II 期研究。
J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22.
3
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.深度测序技术在急性淋巴细胞白血病微小残留病灶检测中的应用。
Blood. 2012 Dec 20;120(26):5173-80. doi: 10.1182/blood-2012-07-444042. Epub 2012 Oct 16.
4
Imaging of multiple myeloma and related plasma cell dyscrasias.多发性骨髓瘤及相关浆细胞疾病的影像学表现。
J Nucl Med. 2012 Jul;53(7):1091-101. doi: 10.2967/jnumed.111.098830. Epub 2012 Jun 12.
5
Lenalidomide in myeloma--a high-maintenance friend.来那度胺治疗骨髓瘤——一位需要长期维持治疗的帮手
N Engl J Med. 2012 May 10;366(19):1836-8. doi: 10.1056/NEJMe1202819.
6
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
7
Lenalidomide after stem-cell transplantation for multiple myeloma.来那度胺用于多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
8
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
9
Latest advances and current challenges in the treatment of multiple myeloma.多发性骨髓瘤治疗的最新进展和当前挑战。
Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43. doi: 10.1038/nrclinonc.2012.15.
10
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.高危细胞遗传学和多参数流式细胞术检测到的持续微量残留病可预测多发性骨髓瘤患者自体干细胞移植后不能持续完全缓解。
Blood. 2012 Jan 19;119(3):687-91. doi: 10.1182/blood-2011-07-370460. Epub 2011 Nov 29.
Zotero 插件